Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Background - The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30%. This study aimed to investigate the efficacy of cemiplimab as first-line or second-line treatment of BCC in a German...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
25 July 2025
|
| In: |
European journal of cancer
Year: 2025, Jahrgang: 225, Pages: 1-7 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2025.115590 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.115590 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804925003727 
|
| Verfasserangaben: | Viola K. DeTemple, Martin Kaatz, Eggert Stockfleth, Christina Scheel, Yenny Angela, Ralf Gutzmer, Ulrike Leiter, Friedegund Meier, Dirk Schadendorf, Elisabeth Livingstone, Christoffer Gebhardt, Imke von Wasielewski, Michael Weichenthal, Peter Mohr, Jessica Hassel, Claudia Pföhler, Jan Christoph Simon, Franziska Jochims, Patrick Terheyden, Jens Ulrich, Sebastian Haferkamp, Konstantin Drexler, Bastian Schilling, Valerie Glutsch, Lucie Heinzerling, Carola Berking, Selma Ugurel, Dirk Tomsitz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1963616863 | ||
| 003 | DE-627 | ||
| 005 | 20260310122223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260306s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2025.115590 |2 doi | |
| 035 | |a (DE-627)1963616863 | ||
| 035 | |a (DE-599)KXP1963616863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a DeTemple, Viola |d 1992- |e VerfasserIn |0 (DE-588)1156360145 |0 (DE-627)1019153512 |0 (DE-576)502144688 |4 aut | |
| 245 | 1 | 0 | |a Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma |c Viola K. DeTemple, Martin Kaatz, Eggert Stockfleth, Christina Scheel, Yenny Angela, Ralf Gutzmer, Ulrike Leiter, Friedegund Meier, Dirk Schadendorf, Elisabeth Livingstone, Christoffer Gebhardt, Imke von Wasielewski, Michael Weichenthal, Peter Mohr, Jessica Hassel, Claudia Pföhler, Jan Christoph Simon, Franziska Jochims, Patrick Terheyden, Jens Ulrich, Sebastian Haferkamp, Konstantin Drexler, Bastian Schilling, Valerie Glutsch, Lucie Heinzerling, Carola Berking, Selma Ugurel, Dirk Tomsitz |
| 264 | 1 | |c 25 July 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 24. Juni 2025, Artikelversion: 27. Juni 2025 | ||
| 500 | |a Gesehen am 06.03.2026 | ||
| 520 | |a Background - The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30%. This study aimed to investigate the efficacy of cemiplimab as first-line or second-line treatment of BCC in a German real-world patient cohort. - Methods - Patients with histologically confirmed locally advanced or metastatic BCC who were treated with cemiplimab were retrospectively identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Therapy outcome was compared between patients receiving first-line cemiplimab and patients treated with cemiplimab in second-line. - Results - 37 patients from 17 skin cancer centers were identified who received cemiplimab. The median follow-up after start of any first-line treatment was 37.1 months, and 17.9 months after initiation of any cemiplimab treatment. Patients who received first-line cemiplimab (n=8) had an ORR of 62.5%, compared to an ORR of 31.0% for patients who received second-line cemiplimab (n=29); Median PFS was 19.8 months for first-line cemiplimab and 5.3 months for second-line cemiplimab. Reinduction with HHIs after progression on second-line cemiplimab resulted in an ORR of 20.0% and a median PFS of 3.8 months. - Conclusion - We demonstrate a comparable outcome for cemiplimab as second-line treatment of BCC in our real-world patient cohort as reported in previous registration studies. Additionally, we found a trend for a more favorable outcome in first-line therapy, suggesting a rationale to further investigate cemiplimab as first-line treatment of advanced BCC. | ||
| 650 | 4 | |a Basal cell carcinoma | |
| 650 | 4 | |a Cemiplimab | |
| 650 | 4 | |a Hedgehog inhibitor | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a Real world data | |
| 700 | 1 | |a Kaatz, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stockfleth, Eggert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheel, Christina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Angela, Yenny |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutzmer, Ralf |d 1968- |e VerfasserIn |0 (DE-588)113713371 |0 (DE-627)502213558 |0 (DE-576)289772095 |4 aut | |
| 700 | 1 | |a Leiter, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meier, Friedegund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Livingstone, Elisabeth |e VerfasserIn |0 (DE-588)1049231325 |0 (DE-627)781379636 |0 (DE-576)403194016 |4 aut | |
| 700 | 1 | |a Gebhardt, Christoffer |d 1976- |e VerfasserIn |0 (DE-588)13051151X |0 (DE-627)503031666 |0 (DE-576)298240289 |4 aut | |
| 700 | 1 | |a Wasielewski, Imke von |e VerfasserIn |0 (DE-588)1357727542 |0 (DE-627)1918611149 |4 aut | |
| 700 | 1 | |a Weichenthal, Michael |e VerfasserIn |0 (DE-588)140953272 |0 (DE-627)623003848 |0 (DE-576)321514157 |4 aut | |
| 700 | 1 | |a Mohr, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Pföhler, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Simon, Jan Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jochims, Franziska |e VerfasserIn |4 aut | |
| 700 | 1 | |a Terheyden, Patrick |d 1970- |e VerfasserIn |0 (DE-588)120128772 |0 (DE-627)080465366 |0 (DE-576)292055285 |4 aut | |
| 700 | 1 | |a Ulrich, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haferkamp, Sebastian |d 1978- |e VerfasserIn |0 (DE-588)132018330 |0 (DE-627)51684296X |0 (DE-576)298896044 |4 aut | |
| 700 | 1 | |a Drexler, Konstantin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schilling, Bastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glutsch, Valerie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzerling, Lucie |d 1969- |e VerfasserIn |0 (DE-588)124732755 |0 (DE-627)537985638 |0 (DE-576)29447224X |4 aut | |
| 700 | 1 | |a Berking, Carola |d 1971- |e VerfasserIn |0 (DE-588)115659714 |0 (DE-627)077390121 |0 (DE-576)290004942 |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Tomsitz, Dirk |d 1985- |e VerfasserIn |0 (DE-588)1024065820 |0 (DE-627)71909187X |0 (DE-576)367884577 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 225(2025) vom: Juli, Artikel-ID 115590, Seite 1-7 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma |
| 773 | 1 | 8 | |g volume:225 |g year:2025 |g month:07 |g elocationid:115590 |g pages:1-7 |g extent:7 |a Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2025.115590 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804925003727 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260306 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |d 60000 |e 60000PU122030923 |k 0/60000/ |p 27 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 15 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1963616863 |e 4930814588 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online verfügbar: 24. Juni 2025, Artikelversion: 27. Juni 2025","Gesehen am 06.03.2026"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"relHost":[{"pubHistory":["28.1992 -"],"disp":"Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaEuropean journal of cancer","origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press"}],"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"part":{"volume":"225","extent":"7","text":"225(2025) vom: Juli, Artikel-ID 115590, Seite 1-7","pages":"1-7","year":"2025"},"recId":"266883400","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}]}],"title":[{"title":"Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma","title_sort":"Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma"}],"physDesc":[{"noteIll":"Illustrationen","extent":"7 S."}],"origin":[{"dateIssuedDisp":"25 July 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["Viola K. DeTemple, Martin Kaatz, Eggert Stockfleth, Christina Scheel, Yenny Angela, Ralf Gutzmer, Ulrike Leiter, Friedegund Meier, Dirk Schadendorf, Elisabeth Livingstone, Christoffer Gebhardt, Imke von Wasielewski, Michael Weichenthal, Peter Mohr, Jessica Hassel, Claudia Pföhler, Jan Christoph Simon, Franziska Jochims, Patrick Terheyden, Jens Ulrich, Sebastian Haferkamp, Konstantin Drexler, Bastian Schilling, Valerie Glutsch, Lucie Heinzerling, Carola Berking, Selma Ugurel, Dirk Tomsitz"]},"person":[{"family":"DeTemple","role":"aut","given":"Viola","display":"DeTemple, Viola"},{"role":"aut","family":"Kaatz","display":"Kaatz, Martin","given":"Martin"},{"family":"Stockfleth","role":"aut","given":"Eggert","display":"Stockfleth, Eggert"},{"display":"Scheel, Christina","given":"Christina","role":"aut","family":"Scheel"},{"role":"aut","family":"Angela","display":"Angela, Yenny","given":"Yenny"},{"given":"Ralf","display":"Gutzmer, Ralf","family":"Gutzmer","role":"aut"},{"role":"aut","family":"Leiter","display":"Leiter, Ulrike","given":"Ulrike"},{"given":"Friedegund","display":"Meier, Friedegund","family":"Meier","role":"aut"},{"display":"Schadendorf, Dirk","given":"Dirk","role":"aut","family":"Schadendorf"},{"display":"Livingstone, Elisabeth","given":"Elisabeth","role":"aut","family":"Livingstone"},{"role":"aut","family":"Gebhardt","display":"Gebhardt, Christoffer","given":"Christoffer"},{"given":"Imke von","display":"Wasielewski, Imke von","family":"Wasielewski","role":"aut"},{"given":"Michael","display":"Weichenthal, Michael","family":"Weichenthal","role":"aut"},{"family":"Mohr","role":"aut","given":"Peter","display":"Mohr, Peter"},{"role":"aut","family":"Hassel","display":"Hassel, Jessica C.","given":"Jessica C."},{"role":"aut","family":"Pföhler","display":"Pföhler, Claudia","given":"Claudia"},{"family":"Simon","role":"aut","given":"Jan Christoph","display":"Simon, Jan Christoph"},{"given":"Franziska","display":"Jochims, Franziska","family":"Jochims","role":"aut"},{"display":"Terheyden, Patrick","given":"Patrick","role":"aut","family":"Terheyden"},{"role":"aut","family":"Ulrich","display":"Ulrich, Jens","given":"Jens"},{"family":"Haferkamp","role":"aut","given":"Sebastian","display":"Haferkamp, Sebastian"},{"family":"Drexler","role":"aut","given":"Konstantin","display":"Drexler, Konstantin"},{"display":"Schilling, Bastian","given":"Bastian","role":"aut","family":"Schilling"},{"given":"Valerie","display":"Glutsch, Valerie","family":"Glutsch","role":"aut"},{"role":"aut","family":"Heinzerling","display":"Heinzerling, Lucie","given":"Lucie"},{"display":"Berking, Carola","given":"Carola","role":"aut","family":"Berking"},{"display":"Ugurel, Selma","given":"Selma","role":"aut","family":"Ugurel"},{"given":"Dirk","display":"Tomsitz, Dirk","family":"Tomsitz","role":"aut"}],"id":{"eki":["1963616863"],"doi":["10.1016/j.ejca.2025.115590"]},"recId":"1963616863"} | ||
| SRT | |a DETEMPLEVIREALWORLDE2520 | ||